Oculus Innovative Sciences(NASDAQ:OCLS) announced the earnings results for Fiscal Year 2017 and Q1. The results came in during After-hours on Jul 28, 2016. Company reported revenue of $3.81M. Analysts estimated a revenue of $3.53M. Earnings per share were $-0.50.
Oculus Innovative Sciences (OCLS) shares turned negative on Thursdays trading session with the shares closing down -0.05 points or -1.34% at a volume of 38,221. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $3.79. The peak price level was also seen at $3.79 while the days lowest was $3.613. Finally the shares closed at $3.68. The 52-week high of the shares is $7.2 while the 52-week low is $3.57. According to the latest information available, the market cap of the company is $15 M.
Several Insider Transactions has been reported to the SEC. On Feb 29, 2016, James J Schutz (CEO) purchased 5,000 shares at $1.00 per share price.
Oculus Innovative Sciences Inc. is a specialty device and pharmaceutical company. The Company develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in both humans and animals. The Company offers wound care products which are sold into the human and animal healthcare markets in the United States Mexico and Europe. The Company also operates a microbiology contract testing laboratory division that provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs as well as testing of products and the Company’s products. The Company’s key technology Microcyn is based on electrically charged oxychlorine small molecules designed to target a range of pathogens that cause disease. The Company completed Phase II trials for Microcyn technology.